Zhou, X. Et Al. 2025. Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.. Alimentary pharmacology & therapeutics .

Zhou, X., Yilmaz, Y., & Zheng, M., (2025). Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.. Alimentary pharmacology & therapeutics .

Zhou, Xiao-Dong, YUSUF YILMAZ, And Ming-Hua Zheng. "Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.," Alimentary pharmacology & therapeutics , 2025

Zhou, Xiao-Dong Et Al. "Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.." Alimentary pharmacology & therapeutics , 2025

Zhou, X. Yilmaz, Y. And Zheng, M. (2025) . "Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.." Alimentary pharmacology & therapeutics .

@article{article, author={Xiao-Dong Zhou Et Al. }, title={Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.}, journal={Alimentary pharmacology & therapeutics}, year=2025}